title: Treatment frequency and efficiency in hemodiafiltration.
abstract: BACKGROUND
  One of the main objectives of dialysis is uremic retention product elimination. Efficiency of dialysis modalities varies both regarding the range of solutes removed and the extent of such removal. We analyzed plasma (or blood) concentrations of marker solutes in intermittent treatment schedules using hemodiafiltration (HDF).
  
  
  METHODS
  Elimination and rebound of uremic solutes were measured in 10 patients (77 ± 12 kg, 66.5 ± 9.2 years) treated with postdilution HDF in one 4-hour treatment and in two 2-hour treatments on consecutive days (Polyflux 2.1 m(2), QB 451 ± 53 ml/min, QD 598 ± 13 ml/min). Blood urea, creatinine, phosphate, β2-microglobulin, complement factor D and advanced glycation end products were analyzed before, during and after HDF for 24-48 h.
  
  
  RESULTS
  Applying two 2-hour HDF treatments on consecutive days resulted in significantly lower plasma (or blood) levels of urea, creatinine, phosphate, β2-microglobulin, and advanced glycation end products after 48 h than using one 4-hour session.
  
  
  CONCLUSIONS
  Increased treatment frequency could further optimize blood purification in HDF therapy.
authors: Gambro Dialysatoren GmbH, Hechingen, Germany. werner.beck @ gambro.com
authors: Werner
authors: W
authors: Beck
authors: Franz
authors: F
authors: Techert
authors: Heike
authors: H
authors: Lebsanft
authors: Ulrike
authors: U
authors: Haug
authors: Reinhold
authors: R
authors: Deppisch
authors: Ingrid
authors: I
authors: Ledebo
authors: Volker
authors: V
authors: Wizemann
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D011416:Complement Factor D / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood; D017583:Hemodiafiltration / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis / Q000295:instrumentation / Q000379:methods*; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000628:therapy*; D016896:Treatment Outcome; D014508:Urea / Q000097:blood; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D015415:Biomarkers; D017127:Glycation End Products, Advanced; D010710:Phosphates; D001613:beta 2-Microglobulin; D014508:Urea; D003404:Creatinine; D011416:Complement Factor D